28.09.2016, 19:12
Merck Launches Viresolve® Pro Shield H for More Robust, Economical Parvovirus Removal
OREANDA-NEWS. Merck, a leading science and technology company, is launching the Viresolve® Pro Shield H for removal of parvoviruses from therapeutic protein feed streams. The new Viresolve® Pro Shield H is designed for use as a prefilter with Viresolve® Pro Devices for more robust, cost-economic viral clearance.
Viresolve® Pro Shield H removes protein aggregates and impurities that foul virus filters in high pH and high conductivity monoclonal antibody (mAb) feed streams. Combined with Viresolve® Pro Device parvovirus retentive filters, the Viresolve® Pro Shield H significantly increases processing capacity, while preserving high virus removal and high flux.
“As feed stream characteristics continue to change, filtration products must evolve in order to enable successful viral clearance to ensure drug safety,” said Andrew Bulpin, Head of Process Solutions Strategic Marketing & Innovation at the life science business of Merck. “Viresolve® Pro Shield H effectively improves aggregate removal and reduces the required virus filtration area needed to process feed streams, while delivering the same high level of virus clearance our customers rely on.”
Recombinant protein, mAb, fusion protein and antibody fragment feed streams can be challenging to process efficiently, both in terms of time and cost, because these proteins tend to aggregate during production. Aggregates can cause virus filters to foul more rapidly, reducing the amount of feed that can be processed and increasing the number of filters required to process the same volume.
Combining the Viresolve® Pro Shield H with the Viresolve® Pro Device provides biopharmaceutical manufacturers with the highest levels of retention assurance and productivity across a broad range of feed stream characteristics. The result is an optimized virus filtration process with lower filter costs, faster processing times and less sensitivity to feed stream variability. Flexible and highly effective, the Viresolve® Pro Shield H and Viresolve® Pro Device is a comprehensive solution to the challenges of diverse viral clearance needs.
“As feed stream characteristics continue to change, filtration products must evolve in order to enable successful viral clearance to ensure drug safety,” said Andrew Bulpin, Head of Process Solutions Strategic Marketing & Innovation at the life science business of Merck. “Viresolve® Pro Shield H effectively improves aggregate removal and reduces the required virus filtration area needed to process feed streams, while delivering the same high level of virus clearance our customers rely on.”
Recombinant protein, mAb, fusion protein and antibody fragment feed streams can be challenging to process efficiently, both in terms of time and cost, because these proteins tend to aggregate during production. Aggregates can cause virus filters to foul more rapidly, reducing the amount of feed that can be processed and increasing the number of filters required to process the same volume.
Combining the Viresolve® Pro Shield H with the Viresolve® Pro Device provides biopharmaceutical manufacturers with the highest levels of retention assurance and productivity across a broad range of feed stream characteristics. The result is an optimized virus filtration process with lower filter costs, faster processing times and less sensitivity to feed stream variability. Flexible and highly effective, the Viresolve® Pro Shield H and Viresolve® Pro Device is a comprehensive solution to the challenges of diverse viral clearance needs.
Комментарии